低剂量紫杉醇持续静脉滴注联合顺铂治疗晚期非小细胞肺癌疗效观察  

Clinical effect of continuous intravenous drip low-dose paclitaxel plus cisplatin treatment for advanced non-small-cell lung cancer

作　　者：成红艳[1] 孙新臣[2] 陈宝安[1] 李苏宜[1] 孙宁[3] 邓雨霞[1] 曹远东[1] 

机构地区：[1]东南大学医学院附属中大医院肿瘤科,江苏南京210009 [2]江苏省人民医院放疗科,江苏南京210029 [3]江苏省肿瘤医院肿瘤科,江苏南京210009

出　　处：《东南大学学报（医学版）》2010年第4期410-413,共4页Journal of Southeast University(Medical Science Edition)

基　　金：国家自然科学基金资助项目(30970792);江苏省卫生厅重点人才基金资助项目(RC:2007110)

摘　　要：目的:观察低剂量紫杉醇(PTX)持续静脉滴注联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的疗效和毒性。方法:纤维支气管镜检查经病理组织学或细胞学证实的32例晚期NSCLC患者,均采用低剂量PTX持续静脉输注联合DDP方案化疗,具体:PTX25mg·m-2·d-1,d1～3、d8～10,静脉滴注16h;DDP75mg·m-2,d1～3、d8～10,静脉滴注,21d为1个疗程,连用2个疗程。结果:32例均可评价疗效,总有效率(完全缓解加部分缓解)为43.8%,而初治患者总有效率高于复治患者,分别为50.0%(9/18)和35.7%(5/14),但差异无统计学意义(P>0.05)。毒副作用主要表现为骨髓抑制、脱发和乏力,其他毒副作用较轻,均在可耐受的范围内。结论:低剂量PTX持续静脉输注联合DDP治疗NSCLC疗效较好,毒副作用可以耐受,值得进一步研究。Objective：To observe the effect and toxicity on advanced non-small-cell lung cancer（NSCLC） after intravenous drip low-dose paclitaxel（PTX） plus cisplatin（DDP）.Methods：32 NSCLC patients were testified by pathologic or cytologic diagnosis,were received low-dose paclitaxel 25 mg·m-2·d-1 by continuous intravenous drip 16 hours,on d 1-3,d 8-10,and cisplatin 75 mg·m-2 by intravenous infusion on d 1-3,d 8-10.The treatment was repeated every 21 days,up to 2 cycles.Therapeutic effect and side effects were observed.Results：In 32 patients,the overall response rate was 43.8%.Response rates of initial treatment and retreatment were 50.0%（9/18） and 35.7%（5/14） respectively.No significant difference was seen between two groups（χ2 = 0.642 9,P 0.05）.The main toxicities were hypoplasia of bonemarrow,alopecie and hypodynamia,and other side effects were mild.All of these could be tolerated by patients.Conclusion：The combination therapy of low-dose paclitaxel plus cisplatin can be the ideal chemotherapy protocol with tolerable toxicity for patients with advanced NSCLC.

关 键 词：紫杉醇 持续静脉滴注 顺铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]